Could a sleep drug curb opioid cravings? new study investigates
NCT ID NCT05829655
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-phase study at the University of Maryland is testing whether suvorexant, a sleep medication, can reduce the desire for drugs in people with opioid use disorder. Researchers will measure how much participants are willing to 'pay' for a study drug in a lab task, and whether suvorexant changes that demand. The study involves 75 adults with moderate to severe opioid use disorder who are not seeking treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Clinical Research Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
suvorexant
What this could lead to
If successful, this could point toward a new way to reduce cravings and drug use in people with opioid use disorder.
What could go wrong
This is a very early, small study (75 people) testing a drug for a non-FDA-approved purpose, so results may not lead to a treatment. The primary outcomes measure behavior in a lab setting, not real-world drug use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.